AbbVie Inc. (ABBV)
Data as of October 19, 2026 · Drug Manufacturers - General
Stockbruh grade: Challenging 0/5 metrics rated Sunny
What does AbbVie Inc. do?
AbbVie Inc. is a global biopharmaceutical company dedicated to the discovery, development, manufacturing, and commercialization of advanced medicines. Its extensive therapeutic portfolio encompasses several key areas: Immunology and Inflammation: Leading products include HUMIRA, an injectable therapy for autoimmune and intestinal Behçet's diseases; SKYRIZI, which addresses moderate to severe plaque psoriasis in adults; and RINVOQ, a JAK inhibitor for moderate to severe active rheumatoid arthritis in adult patients. Oncology and Hematology: For blood cancers, AbbVie provides IMBRUVICA and VENCLEXTA (a BCL-2 inhibitor), both indicated for adult patients with chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL).
Key Numbers
| Metric | Rating | What it means |
|---|
| Returns (5Y) | ⛅ Moderate | 5-year price performance |
| Profitability | ⛅ Moderate | Net margin & return on equity |
| Growth | ⛅ Moderate | Revenue & earnings trend |
| Earnings | ⛅ Moderate | EPS vs analyst expectations |
| Cash & Debt | ⛅ Moderate | Balance sheet strength |
| Price | $285.42 | Market Cap | — |
| Exchange | NYSE | | |
Plain-English Analysis
What's it worth?
Performance has been moderate. Sign up free to see Stockbruh's full valuation analysis including price ratios and plain-English commentary.
Are they building the future?
Growth is mixed — some positive signals, but not consistent. Sign up free for Stockbruh's full growth breakdown.
What's ahead?
Earnings are mixed. Sign up free for the full earnings picture including EPS history and analyst forecasts.